Comprehensive Drug Testing, Inc.

Comprehensive Drug Testing, Inc., doing business as C D T, is a woman-owned small business headquartered in Irvine, California that provides standardized drug screening services — five-panel urine tests, specimen validations, and medical review officer support — to federal agencies exclusively as a prime contractor. The vendor operates primarily under total small business set-asides and competes on GSA Schedules and agency BPAs; 142 prime awards over the source period carry a combined potential value of $8.3 million, with $3.7 million obligated to date.

The vendor's customer concentration is extreme and singular. The Department of the Treasury Bureau of Engraving and Printing accounts for 109 of 142 awards (77% of all awards, 92% of top-five customer coverage) and $1.8 million in combined potential value — a dependency that dominates C D T's federal footprint. BEP awarded the vendor two single-award BPAs: one valued at $325,825 running through September 2028 and another valued at $194,500 through May 2027, both enabling indefinite delivery of drug testing at BEP facilities in Washington, DC, Saginaw, Texas (Washington Currency Facility), and Fort Worth, Texas (Western Currency Facility). The next-largest customer by dollar value is the Department of Justice Justice Management Division (4 awards, $2.7 million), followed by the Department of Homeland Security Customs and Border Protection (9 awards, $1.5 million), DHS US Citizenship and Immigration Services (4 awards, $842 thousand), and DHS Chief Procurement Officer (5 awards, $414 thousand) — together accounting for 22 awards and 89% of combined potential value outside BEP. Activity has contracted sharply: ten awards in 2022, fourteen in 2023, seven in 2024, two in 2025, and one in 2026, signaling either supply stabilization or declining demand after initial ramp-up.

C D T sits on two parent vehicles that anchor its federal presence: the GSA Federal Supply Schedule GS07F0246U (58 task orders, $1.4 million combined potential value) and a GSA Schedule-derived BPA, GS07F0246U-TEPC1368057 (48 task orders, $455 thousand). Three additional vehicles carry smaller volumes: a BEP-specific BPA 2031ZA19A00010 (38 task orders, $189 thousand), an HHS indefinite delivery contract HSBP1010D02405 (7 task orders, $205 thousand), and an HHS indefinite delivery contract HSBP1014D00004 (6 task orders, $831 thousand). The top two vehicles account for 106 of 142 awards. Only one award with ultimate completion in the next twenty-four months appears in the recompete cliff — a $52 thousand call — indicating minimal near-term vehicle or contract expiration risk for most of the portfolio. The vendor has no subcontract footprint; all 142 awards are prime awards, and no federal contractors sub to C D T in the source data. Award scope is narrow: the category concentration reflects 114 awards in Testing Laboratories and Services NAICS, with 137 awards coded to Reference Laboratory Testing PSC, confirming C D T's specialization in standardized drug screening delivery rather than broader occupational health services.

Drug testing, Urine collection, Alcohol, laboratory, medical review officer, hair testing, saliva testing, mobile collections, SAPPA Certified, DOT non-DOT Drug Testing, Pre-employment, Reasonable Suspicion, Return to Duty Testing, Post Accident Testing